Covance Announces Exclusive Relationship with INphoton, LLC For Microscopy Imaging Services
Covance and INphoton LLC today announced a collaborative relationship which will grant Covance exclusive global access to INphoton’s intravital microscopy imaging technology and expertise.
The new services offered as a result of the companies’ collaboration will include intravital microscopy and associated 3D image reconstruction and will offer clients:
- High resolution quantitative assays of the in vivo physiological effects of drugs;
- High resolution quantitative assays of in vivo drug distribution and pharmacokinetics;
- Characterization of the mechanisms and kinetics of renal and hepatic drug clearance; and
- Consultation on the feasibility, design and interpretation of imaging studies.
Dr. Michael A. Dorato, Vice President of Covance Discovery Services, stated, “The unique imaging capabilities of both organizations will allow our scientific teams to integrate intravital microscopy with Covance’s extensive molecular and anatomical imaging expertise focusing on specific client queries in the early discovery/development phase. The ultimate benefit is enabling our clients to make resource- and time-saving decisions on compounds earlier in the drug development process.”
Intravital microscopy is a technique that provides quantitative, in vivo molecular imaging at subcellular resolution, resulting in a cost-effective approach to accelerate preclinical drug development. State-of-the-art multiphoton microscopy combined with novel surgical techniques and multiple fluorophores allow in vivo imaging at subcellular resolution. These high-content imaging technologies provide visibility of quantitative organ, cellular and subcellular distribution of potential therapeutic compounds as well as physiologic data, facilitating an understanding of efficacy and safety. Clients have found that the insights provided by in vivo multiphoton microscopy provide for more in-depth decision making data.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
